NRx Pharmaceuticals signs license agreement for D-cycloserine patent claim

NRx Pharmaceuticals announced it has made advances in developing NRX-101 to treat Chronic Pain. The company has signed a license agreement for US Patent 8,653,120 that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. Additional published non-clinical data previously reported demonstrate that NRX-101 is not neurotoxic1 and not addictive. NRx has signed an agreement with Vania Apkarian to join the NRx Pharmaceuticals Scientific Advisory Board.